Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DNA rich in unmethylated CG motifs (CpGs) engage Toll-Like Receptor 9 (TLR-9) in endosomes and are well described stimulators of the innate and adaptive immune system. CpGs therefore can efficiently improve vaccines' immunogenicity. Packaging CpGs into nanoparticles, in particular into virus-like particles (VLPs), improves the pharmacological characteristics of CpGs as the protein shell protects them from DNAse activity and delivers the oligomers to the endosomal compartments of professional antigen presenting cells (APCs). The current consensus in packaging and delivering CpGs in VLP-based vaccines is that both adjuvants and antigens should be kept in close proximity (i.e. physically linked) to ensure delivery of antigens and adjuvants to the same APCs. In the current study, we harness the draining properties of the lymphatic system and show that also non-linked VLPs are efficiently co-delivered to the same APCs in lymph nodes. Specifically, we have shown that CpGs can be packaged in one VLP and mixed with another VLP displaying the antigen prior to administration in vivo. Both VLPs efficiently reached the same draining lymph node where they were taken up and processed by the same APCs, namely dendritic cells and macrophages. This resulted in induction of specific CTLs producing cytokines and killing target cells in vivo at levels seen when using VLPs containing both CpGs and chemically conjugated antigen. Thus, delivery of antigens and adjuvants in separate nanoparticles eliminates the need of physical conjugation and thus can be beneficial when designing precision medicine VLP-based vaccines or help to re-formulate existing VLP vaccines not naturally carrying immunostimulatory sequences.

Original publication

DOI

10.1016/j.jconrel.2017.02.031

Type

Journal article

Journal

Journal of controlled release : official journal of the Controlled Release Society

Publication Date

04/2017

Volume

251

Pages

92 - 100

Addresses

University of Oxford, Roosevelt Dr, Oxford OX3 7BN, UK; Qatar Foundation (QRLP), Doha, State of Qatar. Electronic address: mona.mohsen@kellogg.ox.ac.uk.

Keywords

Lymph Nodes, Dendritic Cells, Macrophages, Animals, Mice, Inbred C57BL, Mice, Allolevivirus, Lymphocytic choriomeningitis virus, Adjuvants, Immunologic, Antigens, Viral, Vaccination, Drug Delivery Systems, CpG Islands, Toll-Like Receptor 9, Nanoparticles, Vaccines, Virus-Like Particle